A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

What this study is about

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

Who can join (things the study team will check)

✅ You may be able to join if…

• Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study Parent Clinical Trial-Specific Criteria:
• Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved => EASI50 response from study baseline

🚫 You may not be able to join if…

• Evidence of other skin conditions that would interfere with the assessment of AD
• Withdrawal of consent and/or premature discontinuation from parent study
• Any permanent discontinuation of study drug in parent study
• History of severe allergic reaction or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of Afimkibart

Where this trial is running

• Hamilton Research, LLC, Alpharetta, Georgia, United States
• Revival Research Institute, LLC, Troy, Michigan, United States
• Best Skin Research LLC, Camp Hill, Pennsylvania, United States
• Centro de Estudos em Terapias Inovadoras ? CETI, Curitiba, Paraná, Brazil
• Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
• Hospital de Clnicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
• UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu, Botucatu, São Paulo, Brazil
• Centro de Pesquisa São Lucas, Campinas, São Paulo, Brazil
• HMCG - Hospital e Maternidade Dr. Christovo da Gama, Santo Andr, São Paulo, Brazil
• Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, Sao Jose Rio Preto, São Paulo, Brazil
• Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A, Rio de Janeiro, Brazil
• DermEffects, London, Ontario, Canada

+ 12 more sites.

Who to contact

Reference Study ID Number: CS45943 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07223697.